Erasca (ERAS) Competitors $1.34 -0.03 (-1.82%) As of 03:15 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERAS vs. DYN, ADPT, SDGR, BHVN, EWTX, MESO, SPRY, ETNB, EVO, and JANXShould you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Dyne Therapeutics (DYN), Adaptive Biotechnologies (ADPT), Schrödinger (SDGR), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Mesoblast (MESO), ARS Pharmaceuticals (SPRY), 89bio (ETNB), Evotec (EVO), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry. Erasca vs. Its Competitors Dyne Therapeutics Adaptive Biotechnologies Schrödinger Biohaven Edgewise Therapeutics Mesoblast ARS Pharmaceuticals 89bio Evotec Janux Therapeutics Erasca (NASDAQ:ERAS) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, community ranking, profitability, analyst recommendations and risk. Does the MarketBeat Community favor ERAS or DYN? Dyne Therapeutics received 22 more outperform votes than Erasca when rated by MarketBeat users. Likewise, 80.00% of users gave Dyne Therapeutics an outperform vote while only 73.17% of users gave Erasca an outperform vote. CompanyUnderperformOutperformErascaOutperform Votes3073.17% Underperform Votes1126.83% Dyne TherapeuticsOutperform Votes5280.00% Underperform Votes1320.00% Do insiders & institutionals believe in ERAS or DYN? 67.8% of Erasca shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 14.4% of Erasca shares are held by company insiders. Comparatively, 20.8% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ERAS or DYN more profitable? Erasca's return on equity of -36.56% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -36.56% -31.08% Dyne Therapeutics N/A -52.83%-48.84% Which has stronger valuation & earnings, ERAS or DYN? Dyne Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$161.65M-$0.62-2.17Dyne TherapeuticsN/AN/A-$317.42M-$3.59-2.87 Does the media refer more to ERAS or DYN? In the previous week, Dyne Therapeutics had 25 more articles in the media than Erasca. MarketBeat recorded 25 mentions for Dyne Therapeutics and 0 mentions for Erasca. Dyne Therapeutics' average media sentiment score of 0.15 beat Erasca's score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Erasca Neutral Dyne Therapeutics Neutral Which has more volatility and risk, ERAS or DYN? Erasca has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Do analysts rate ERAS or DYN? Erasca presently has a consensus price target of $4.57, suggesting a potential upside of 239.88%. Dyne Therapeutics has a consensus price target of $43.93, suggesting a potential upside of 325.83%. Given Dyne Therapeutics' higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryDyne Therapeutics beats Erasca on 10 of the 15 factors compared between the two stocks. Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERAS vs. The Competition Export to ExcelMetricErascaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$381.03M$2.79B$5.16B$8.58BDividend YieldN/A2.69%5.38%4.24%P/E Ratio-2.1721.0325.6919.24Price / SalesN/A293.16401.57156.75Price / CashN/A40.9225.4426.73Price / Book0.907.327.865.62Net Income-$161.65M-$55.10M$3.15B$248.36M7 Day Performance-4.27%-3.33%-1.54%-0.39%1 Month Performance10.25%5.04%3.38%3.51%1 Year Performance-36.26%-2.47%40.74%15.15% Erasca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERASErasca2.0202 of 5 stars$1.35-1.8%$4.57+239.9%-35.1%$381.03MN/A-2.17120DYNDyne Therapeutics2.6103 of 5 stars$13.82-4.1%$44.93+225.1%-70.5%$1.57BN/A-3.88100High Trading VolumeADPTAdaptive Biotechnologies2.73 of 5 stars$10.29-0.3%$9.83-4.4%+220.4%$1.56B$189.53M-9.44790SDGRSchrödinger2.3528 of 5 stars$21.20-1.1%$32.80+54.7%+8.9%$1.56B$230.49M-9.06790BHVNBiohaven3.1526 of 5 stars$15.19-1.7%$59.46+291.4%-56.8%$1.55BN/A-1.62239EWTXEdgewise Therapeutics2.9202 of 5 stars$14.68-4.0%$39.78+171.0%-16.1%$1.54BN/A-9.7960MESOMesoblast2.5509 of 5 stars$12.30+4.4%$18.00+46.3%+48.9%$1.51B$5.67M0.0080Positive NewsSPRYARS Pharmaceuticals3.1995 of 5 stars$15.16-1.5%$31.00+104.5%+93.4%$1.49B$97.12M-29.7390Positive NewsInsider TradeETNB89bio2.8405 of 5 stars$10.05-3.5%$26.43+163.0%+18.3%$1.47BN/A-3.4540Positive NewsEVOEvotec2.0446 of 5 stars$4.13-3.3%$5.93+43.7%-16.1%$1.47B$788.22M0.004,200High Trading VolumeJANXJanux Therapeutics2.7387 of 5 stars$23.61-5.2%$95.25+303.4%-42.4%$1.40B$9.34M-20.1830Positive News Related Companies and Tools Related Companies Dyne Therapeutics Alternatives Adaptive Biotechnologies Alternatives Schrödinger Alternatives Biohaven Alternatives Edgewise Therapeutics Alternatives Mesoblast Alternatives ARS Pharmaceuticals Alternatives 89bio Alternatives Evotec Alternatives Janux Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERAS) was last updated on 6/23/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ERAS Stock Free ERAS Stock Alerts